| Ytd | -54.78% | |
| 1y | -52.42% |
| Open | 0.93 | Prev Close | 0.92 | Low | 0.91 | High | 0.93 | Mkt Cap | 113.73M |
| Vol | 91.74K | Avg Vol | 1.48M | EPS | -0.65 | P/E | N/A | Forward P/E | -2.15 |
| Beta | 0.98 | Short Ratio | 2.46 | Inst. Own | 57.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.13 | 200-d Avg | 1.60 | 1yr Est | 10.25 |
MIST News
HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST)
Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the developme
Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Milestone Pharmaceuticals
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's p
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.21) per share which missed
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's
Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overwei
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) reported first-quarter earnings on Wednesday before th
Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development
EU decision delay for Milestone Pharmaceuticals etripamil, despite strong U.S. launch progress, soli
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.16) per share which met the
Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16
CARDAMYST is a prescription medication indicated for the conversion of acute symptomatic episodes of
HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST)
Aptar Group, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and pr
Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overwei
TD Cowen analyst Ritu Baral upgrades Milestone Pharmaceuticals (NASDAQ:MIST) from Hold to Buy and
HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST)
The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in
RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Ph
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal sp
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.12) per share which beat th
Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the developmen
Wells Fargo analyst Mohit Bansal initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) wi
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.20) per share which missed
FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $
Milestone® Pharmaceuticals Inc. ("Milestone") (NASDAQ:MIST), a biopharmaceutical company foc
HC Wainwright & Co. analyst Brandon Folkes assumes Milestone Pharmaceuticals (NASDAQ:MIST) wi
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.31) per share which missed
HC Wainwright & Co. analyst Patrick Trucchio maintains Milestone Pharmaceuticals (NASDAQ:MIST
HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIS
Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from
The FDA did not raise any concerns regarding etripamil clinical safety or efficacy data and highligh
HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIS
HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIS